Sign in
Taking people in United StatesPhase 2

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Key facts

Who runs it
Henry M. Jackson Foundation for the Advancement of Military Medicine
Where
El Paso, Fort Bragg, Pittsburgh, and Tacoma, United StatesSee the 4 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
404 people, planned
Started
19 Jul 2022
Expected to end
19 May 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Erenumab 140 Mg/mL Subcutaneous Solution
  • Placebo
Record updated
22 February 2024

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Male or female ≥18 and ≤50 years of age
  • mTBI from any cause including impact, rotational acceleration, blast, or a combination, has occurred within the prior 7 days
  • PTH has occurred within the prior 7 days
  • Able to provide informed consent
  • Likely to stay in the same geographical area for the duration of study
  • Has a personal health care provider for standard of care PTH and TBI, including education, diagnostic procedures including neuroimaging and treatment, as deemed clinically indicated by the health care provider

Who cannot take part

  • Participants with ongoing chronic migraine or other chronic daily headache disorders at the time of injury
  • Sustained a moderate or severe TBI, rather than mTBI, indicated with at least 1 of the following associated with head injury:; abnormal structural imaging; loss of consciousness for >30 minutes; alteration of consciousness/mental state for >24 hours 3. post-traumatic amnesia for >1 day

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

This trial is currently available in United States.

  • William Beaumont Army Medical CenterEl Paso, United StatesContact: Cecilia Valdovinos, NPTaking people
  • Womack Army Medical Center - Fort LibertyFort Bragg, United StatesContact: Jennifer Robles, RNTaking people
  • University of Pittsburgh Concussion Research LaboratoryPittsburgh, United StatesContact: Courtney PerryNot yet recruiting
  • Madigan Army Medical CenterTacoma, United StatesContact: Janel CuevasNot yet recruiting

About the trial

What the trial wants to find out

This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).

The 2 groups in the trial

  • Active DrugTreatment being tested

    Erenumab administered once monthly via two 70-mg subcutaneous injections at 3 time points over a 12-week period.

    Treatment: Erenumab 140 Mg/mL Subcutaneous Solution

  • PlaceboPlacebo, for comparison

    Placebo administered once monthly via two subcutaneous injections at 3 time points over a 12-week period.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension
Criteria questions
Built from NCT05049057, who can take part
Record updated
22 February 2024